RE: Dose escalation1 Sep 2022 09:06
Kevin
I think they are just stating the facts as they know them, that Doxorubicin market will be £1.38bn in 2024. Of course Doxorubicin is only one of a series of Anthracyclines Chemo drugs, and I imagine that if the AVCT product proves a success, it will more than likely increase Doxorubicin market share, and also likely encourage other similar Chemo drugs to find a similar solution - with AVCT in an attractive position.
All supposition, but think that the £1.38Bn is very much a minimum figure based on current Doxorubicin market share expectation without our product. Mayt